Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice

Jong Ho Kim, Yoo Shin Kim, Kyeongsoon Park, Seulki Lee, Hae Yun Nam, Kyung Hyun Min, Hyung Gon Jo, Jae Hyung Park, Kuiwon Choi, Seo Young Jeong, Rang Woon Park, In-San Kim, Kwang Meyung Kim, Ick Chan Kwon

Research output: Contribution to journalArticle

301 Citations (Scopus)

Abstract

To make a tumor targeting nano-sized drug delivery system, biocompatible and biodegradable glycol chitosan (Mw = 250 kDa) was modified with hydrophobic cholanic acid. The resulting hydrophobically modified glycol chitosans (HGCs) that formed nano-sized self-aggregates in an aqueous medium were investigated as an anticancer drug carrier in cancer treatment. Insoluble anticancer drug, cisplatin (CDDP), was easily encapsulated into the hydrophobic cores of HGC nanoparticles by a dialysis method, wherein the drug loading efficiency was about 80%. The CCDP-encapsulated HGC (CDDP-HGC) nanoparticles were well-dispersed in aqueous media and they formed a nanoparticles structure with a mean diameter about 300-500 nm. As a nano-sized drug carrier, the CDDP-HGC nanoparticles released the drug in a sustained manner for a week and they were also less cytotoxic than was free CDDP, probably because of sustained release of CDDP from the HGC nanoparticles. The tumor targeting ability of CDDP-HGC nanoparticles was confirmed by in vivo live animal imaging with near-infrared fluorescence Cy5.5-labeled CDDP-HGC nanoparticles. It was observed that CDDP-HGC nanoparticles were successfully accumulated by tumor tissues in tumor-bearing mice, because of the prolonged circulation and enhanced permeability and retention (EPR) effect of CDDP-HGC nanoparticles in tumor-bearing mice. As expected, the CDDP-HGC nanoparticles showed higher antitumor efficacy and lower toxicity compared to free CDDP, as shown by changes in tumor volumes, body weights, and survival rates, as well as by immunohistological TUNEL assay data. Collectively, the present results indicate that HGC nanoparticles are a promising carrier for the anticancer drug CDDP.

Original languageEnglish
Pages (from-to)41-49
Number of pages9
JournalJournal of Controlled Release
Volume127
Issue number1
DOIs
Publication statusPublished - 2008 Apr 7
Externally publishedYes

Fingerprint

Nanoparticles
Cisplatin
Neoplasms
Drug Carriers
glycol-chitosan
Pharmaceutical Preparations
In Situ Nick-End Labeling
Drug Delivery Systems
Tumor Burden
Dialysis
Permeability
Fluorescence
Body Weight

Keywords

  • Cisplatin
  • Drug delivery system
  • Hydrophobically modified glycol chitosan
  • In vivo antitumor efficacy
  • Passive tumor targeting
  • Self-assembled nanoparticles

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Kim, J. H., Kim, Y. S., Park, K., Lee, S., Nam, H. Y., Min, K. H., ... Kwon, I. C. (2008). Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. Journal of Controlled Release, 127(1), 41-49. https://doi.org/10.1016/j.jconrel.2007.12.014

Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. / Kim, Jong Ho; Kim, Yoo Shin; Park, Kyeongsoon; Lee, Seulki; Nam, Hae Yun; Min, Kyung Hyun; Jo, Hyung Gon; Park, Jae Hyung; Choi, Kuiwon; Jeong, Seo Young; Park, Rang Woon; Kim, In-San; Kim, Kwang Meyung; Kwon, Ick Chan.

In: Journal of Controlled Release, Vol. 127, No. 1, 07.04.2008, p. 41-49.

Research output: Contribution to journalArticle

Kim, JH, Kim, YS, Park, K, Lee, S, Nam, HY, Min, KH, Jo, HG, Park, JH, Choi, K, Jeong, SY, Park, RW, Kim, I-S, Kim, KM & Kwon, IC 2008, 'Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice', Journal of Controlled Release, vol. 127, no. 1, pp. 41-49. https://doi.org/10.1016/j.jconrel.2007.12.014
Kim, Jong Ho ; Kim, Yoo Shin ; Park, Kyeongsoon ; Lee, Seulki ; Nam, Hae Yun ; Min, Kyung Hyun ; Jo, Hyung Gon ; Park, Jae Hyung ; Choi, Kuiwon ; Jeong, Seo Young ; Park, Rang Woon ; Kim, In-San ; Kim, Kwang Meyung ; Kwon, Ick Chan. / Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. In: Journal of Controlled Release. 2008 ; Vol. 127, No. 1. pp. 41-49.
@article{c6594fdfd34c4ee78d3ebb05dec10671,
title = "Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice",
abstract = "To make a tumor targeting nano-sized drug delivery system, biocompatible and biodegradable glycol chitosan (Mw = 250 kDa) was modified with hydrophobic cholanic acid. The resulting hydrophobically modified glycol chitosans (HGCs) that formed nano-sized self-aggregates in an aqueous medium were investigated as an anticancer drug carrier in cancer treatment. Insoluble anticancer drug, cisplatin (CDDP), was easily encapsulated into the hydrophobic cores of HGC nanoparticles by a dialysis method, wherein the drug loading efficiency was about 80{\%}. The CCDP-encapsulated HGC (CDDP-HGC) nanoparticles were well-dispersed in aqueous media and they formed a nanoparticles structure with a mean diameter about 300-500 nm. As a nano-sized drug carrier, the CDDP-HGC nanoparticles released the drug in a sustained manner for a week and they were also less cytotoxic than was free CDDP, probably because of sustained release of CDDP from the HGC nanoparticles. The tumor targeting ability of CDDP-HGC nanoparticles was confirmed by in vivo live animal imaging with near-infrared fluorescence Cy5.5-labeled CDDP-HGC nanoparticles. It was observed that CDDP-HGC nanoparticles were successfully accumulated by tumor tissues in tumor-bearing mice, because of the prolonged circulation and enhanced permeability and retention (EPR) effect of CDDP-HGC nanoparticles in tumor-bearing mice. As expected, the CDDP-HGC nanoparticles showed higher antitumor efficacy and lower toxicity compared to free CDDP, as shown by changes in tumor volumes, body weights, and survival rates, as well as by immunohistological TUNEL assay data. Collectively, the present results indicate that HGC nanoparticles are a promising carrier for the anticancer drug CDDP.",
keywords = "Cisplatin, Drug delivery system, Hydrophobically modified glycol chitosan, In vivo antitumor efficacy, Passive tumor targeting, Self-assembled nanoparticles",
author = "Kim, {Jong Ho} and Kim, {Yoo Shin} and Kyeongsoon Park and Seulki Lee and Nam, {Hae Yun} and Min, {Kyung Hyun} and Jo, {Hyung Gon} and Park, {Jae Hyung} and Kuiwon Choi and Jeong, {Seo Young} and Park, {Rang Woon} and In-San Kim and Kim, {Kwang Meyung} and Kwon, {Ick Chan}",
year = "2008",
month = "4",
day = "7",
doi = "10.1016/j.jconrel.2007.12.014",
language = "English",
volume = "127",
pages = "41--49",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice

AU - Kim, Jong Ho

AU - Kim, Yoo Shin

AU - Park, Kyeongsoon

AU - Lee, Seulki

AU - Nam, Hae Yun

AU - Min, Kyung Hyun

AU - Jo, Hyung Gon

AU - Park, Jae Hyung

AU - Choi, Kuiwon

AU - Jeong, Seo Young

AU - Park, Rang Woon

AU - Kim, In-San

AU - Kim, Kwang Meyung

AU - Kwon, Ick Chan

PY - 2008/4/7

Y1 - 2008/4/7

N2 - To make a tumor targeting nano-sized drug delivery system, biocompatible and biodegradable glycol chitosan (Mw = 250 kDa) was modified with hydrophobic cholanic acid. The resulting hydrophobically modified glycol chitosans (HGCs) that formed nano-sized self-aggregates in an aqueous medium were investigated as an anticancer drug carrier in cancer treatment. Insoluble anticancer drug, cisplatin (CDDP), was easily encapsulated into the hydrophobic cores of HGC nanoparticles by a dialysis method, wherein the drug loading efficiency was about 80%. The CCDP-encapsulated HGC (CDDP-HGC) nanoparticles were well-dispersed in aqueous media and they formed a nanoparticles structure with a mean diameter about 300-500 nm. As a nano-sized drug carrier, the CDDP-HGC nanoparticles released the drug in a sustained manner for a week and they were also less cytotoxic than was free CDDP, probably because of sustained release of CDDP from the HGC nanoparticles. The tumor targeting ability of CDDP-HGC nanoparticles was confirmed by in vivo live animal imaging with near-infrared fluorescence Cy5.5-labeled CDDP-HGC nanoparticles. It was observed that CDDP-HGC nanoparticles were successfully accumulated by tumor tissues in tumor-bearing mice, because of the prolonged circulation and enhanced permeability and retention (EPR) effect of CDDP-HGC nanoparticles in tumor-bearing mice. As expected, the CDDP-HGC nanoparticles showed higher antitumor efficacy and lower toxicity compared to free CDDP, as shown by changes in tumor volumes, body weights, and survival rates, as well as by immunohistological TUNEL assay data. Collectively, the present results indicate that HGC nanoparticles are a promising carrier for the anticancer drug CDDP.

AB - To make a tumor targeting nano-sized drug delivery system, biocompatible and biodegradable glycol chitosan (Mw = 250 kDa) was modified with hydrophobic cholanic acid. The resulting hydrophobically modified glycol chitosans (HGCs) that formed nano-sized self-aggregates in an aqueous medium were investigated as an anticancer drug carrier in cancer treatment. Insoluble anticancer drug, cisplatin (CDDP), was easily encapsulated into the hydrophobic cores of HGC nanoparticles by a dialysis method, wherein the drug loading efficiency was about 80%. The CCDP-encapsulated HGC (CDDP-HGC) nanoparticles were well-dispersed in aqueous media and they formed a nanoparticles structure with a mean diameter about 300-500 nm. As a nano-sized drug carrier, the CDDP-HGC nanoparticles released the drug in a sustained manner for a week and they were also less cytotoxic than was free CDDP, probably because of sustained release of CDDP from the HGC nanoparticles. The tumor targeting ability of CDDP-HGC nanoparticles was confirmed by in vivo live animal imaging with near-infrared fluorescence Cy5.5-labeled CDDP-HGC nanoparticles. It was observed that CDDP-HGC nanoparticles were successfully accumulated by tumor tissues in tumor-bearing mice, because of the prolonged circulation and enhanced permeability and retention (EPR) effect of CDDP-HGC nanoparticles in tumor-bearing mice. As expected, the CDDP-HGC nanoparticles showed higher antitumor efficacy and lower toxicity compared to free CDDP, as shown by changes in tumor volumes, body weights, and survival rates, as well as by immunohistological TUNEL assay data. Collectively, the present results indicate that HGC nanoparticles are a promising carrier for the anticancer drug CDDP.

KW - Cisplatin

KW - Drug delivery system

KW - Hydrophobically modified glycol chitosan

KW - In vivo antitumor efficacy

KW - Passive tumor targeting

KW - Self-assembled nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=40649100957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40649100957&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2007.12.014

DO - 10.1016/j.jconrel.2007.12.014

M3 - Article

C2 - 18234388

AN - SCOPUS:40649100957

VL - 127

SP - 41

EP - 49

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -